Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Increases By 33.1%

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI - Get Free Report) was the recipient of a significant growth in short interest in October. As of October 15th, there was short interest totalling 165,900 shares, a growth of 33.1% from the September 30th total of 124,600 shares. Approximately 3.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 46,700 shares, the days-to-cover ratio is presently 3.6 days.

Wall Street Analyst Weigh In

Several research firms have commented on BCLI. StockNews.com started coverage on shares of Brainstorm Cell Therapeutics in a report on Wednesday, October 9th. They set a "hold" rating for the company. Maxim Group raised Brainstorm Cell Therapeutics from a "hold" rating to a "buy" rating and set a $30.00 price target for the company in a research note on Thursday, July 11th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC bought a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 7,917,653 shares of the biotechnology company's stock, valued at approximately $2,680,000. Armistice Capital LLC owned 11.30% of Brainstorm Cell Therapeutics as of its most recent SEC filing. Institutional investors own 14.33% of the company's stock.

Brainstorm Cell Therapeutics Stock Performance

BCLI stock traded up $0.07 during trading on Friday, hitting $1.96. 49,745 shares of the company's stock traded hands, compared to its average volume of 52,560. Brainstorm Cell Therapeutics has a 52 week low of $1.88 and a 52 week high of $11.89. The stock has a market capitalization of $137.33 million, a price-to-earnings ratio of -6.12 and a beta of 0.33. The business has a fifty day simple moving average of $3.50 and a 200 day simple moving average of $5.35.

Brainstorm Cell Therapeutics (NASDAQ:BCLI - Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.60) EPS for the quarter, hitting the consensus estimate of ($0.60). During the same period in the previous year, the business posted ($4.05) earnings per share. Research analysts forecast that Brainstorm Cell Therapeutics will post -2.85 earnings per share for the current fiscal year.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.